This content is machine translated Type 2 diabetes: SURE Switzerland study New “real world” data on semaglutide in subcutaneous form convincing The prospective, multicenter observational study SURE Switzerland investigated the efficacy of once-weekly subcutaneously administered semaglutide in patients with type 2 diabetes in clinical practice. Among other things, it was shown…
